CagriSema ObesityWeek 2026 slate lists REDEFINE 9 and Wegovy pill data but no numbers

PLAINSBORO, NJ Novo Nordisk said on October 29 that its CagriSema ObesityWeek 2026 program will include the primary results of REDEFINE 9, a trial of lower CagriSema doses. The company will present 26 abstracts from its obesity portfolio in Washington from November 14 to 17, along with Wegovy pill real world data and full STEP Young results in children. The announcement named studies, authors and session times. It gave no efficacy or safety figures for any of them, so the size of each result is not yet known.

What Novo plans to show in Washington

CagriSema sits at the center of the program. Novo said it will present the primary results of REDEFINE 9 and several post hoc analyses of REDEFINE 1, its pivotal Phase 3 trial. The analyses cover weight related quality of life, physical and psychosocial function, early response and weight loss curves, and effects by baseline body mass index and obesity related complications. One more abstract models how CagriSema might affect the primary prevention of heart disease in US adults with overweight or obesity. That is a projection from a model, not an outcomes trial. Another title says cagrilintide, one of the two parts of CagriSema, protects bone mass during weight loss. The release does not say whether that work was done in people or in animals.

The company's list of presentations gives 17 titles and one evening symposium, so not all 26 abstracts are named. Most of the named titles concern Wegovy, the semaglutide brand sold as a weekly injection and a daily tablet. Martin Holst Lange, Novo's chief scientific officer, said people with obesity "can have different experiences and treatment needs at different stages of life." He said the meeting would cover CagriSema, oral and injectable Wegovy, and semaglutide injection in children aged 6 to under 12. Several posters share the same Sunday afternoon slot, and the CagriSema ObesityWeek 2026 sessions run across three days. The table below sets out the dated sessions the company named for its main studies.

REDEFINE 9 tests lower CagriSema doses

REDEFINE 9 is the only new trial readout in the CagriSema ObesityWeek 2026 program. Novo describes it as a test of low doses of CagriSema in adults with overweight or obesity. The poster title names two dose pairings, both below the strength in the company's US filing. The poster lists S. Wharton as first author. The release gives no trial size, length, comparator or result. It also does not say what Novo hopes a lower dose will achieve, beyond a headline that points to weight loss potential at reduced doses. Readers will need the poster to judge whether lower doses keep most of the weight loss while easing side effects. Until then, any claim about the trial's outcome would be a guess. The company has not said whether REDEFINE 9 will support a future filing.

In REDEFINE 1, Novo reported average weight loss of 20.4% at 68 weeks with CagriSema against 3.0% with placebo, counting everyone whether or not they stayed on treatment.

The benchmark is REDEFINE 1, which enrolled 3,417 adults without diabetes. In REDEFINE 1, Novo reported average weight loss of 20.4% at 68 weeks with CagriSema against 3.0% with placebo, counting everyone whether or not they stayed on treatment. If all participants had stayed on treatment, the company estimated 22.7% against 2.3%. Gastrointestinal side effects were reported in 79.6% of the CagriSema group and 39.9% on placebo, and 5.9% stopped CagriSema because of adverse events. Novo filed a New Drug Application with the FDA on December 18, 2025, and said then that it expected the agency to review it in 2026. The October release says no regulator anywhere has yet approved CagriSema.

Wegovy pill real world data rely on company programs

The Wegovy pill real world data come from four named projects. OCTANE describes adults who started oral semaglutide for weight management through one US telehealth platform, including people new to treatment. It reports weight, food noise and other patient reported outcomes at 3 months. SIGNAL follows treatment naive adults who started the Wegovy injection on the same platform for 6 months. It measures food noise, the persistent thoughts about eating some patients describe, with a scale called RAID FN. SWEEP looks at self reported weight outcomes and patient experience among people who began the pill inside Novo's own digital support program. OPTIC compares medication preferences in adults aged 65 and older with those of younger adults. A separate ORACLE poster compares the short term cost of weight control with oral semaglutide and Lilly's orforglipron.

These designs have limits that the release does not discuss. Real world cohorts drawn from a telehealth service or a company support program may not resemble the wider population with obesity. Self reported weight is less reliable than weight measured in a clinic. None of the four descriptions mentions a control group, so changes over time cannot be pinned on the drug alone. A recent Wegovy pill switch study of 194 adults had the same weaknesses. The tablet itself is approved, which is why it can be studied in routine care; the first tablet GLP 1 for weight management cleared the FDA because Novo found a way to get a peptide through the gut. The new posters may show how people use it, not how well it works against a comparator.

STEP Young puts semaglutide in children on the agenda

STEP Young tested once weekly semaglutide injection, added to a reduced calorie diet and more physical activity, in children aged 6 to under 12 with obesity. Novo said full results will be given as an oral presentation on Monday, November 16, with simultaneous publication. The talk lists A.M. Jastreboff as first author. The release does not name the journal and gives no figures on weight change, growth or side effects. It notes that US approval of semaglutide injection does not extend to children younger than 12. That makes this an investigational use, and Novo describes the coming data as the full results of the trial. Families and doctors should read the published paper, including its safety tables, before drawing conclusions about semaglutide in children.

What comes next is the data. Posters and talks run from November 14 to 17, and the key questions are plain. How much weight did people lose on the lower CagriSema doses, and did fewer people stop because of nausea or vomiting? What did STEP Young show for growth and safety in children? Do the real world cohorts report measured weight or only self reported figures? On the regulatory side, the CagriSema ObesityWeek 2026 data arrive while the drug remains unapproved, ten months after Novo filed its US application. Novo has not said when it expects a decision. Peptide Zone will report the figures once the abstracts and the STEP Young paper are public.

Conclusion

Novo's October 29 announcement is a schedule, not a readout. The CagriSema ObesityWeek 2026 program promises REDEFINE 9 primary results, more REDEFINE 1 analyses, STEP Young data in children and several real world Wegovy studies, but it contains no numbers. The firmest benchmark remains REDEFINE 1, with 20.4% average weight loss at 68 weeks against 3.0% on placebo. Readers should judge the new results against that figure, check for control groups and measured outcomes, and remember that CagriSema is still unapproved. This report is for research context and is not medical advice.